| Duarte, 2021[13] | Outbreak of COVID-19 to April, 2021 | Retrospective cohort | ADT versus non-ADT | Cumulative incidence of Death | Brazilian Unified Health System |
| Fujiwara, 2021[38] | Apr to Jun, 2020 | Retrospective cohort (pilot study) | Prostate cancer which switched from GnRH antagonist to long-acting LH-RH agonist | Serum testosterone, PSA | Cancer Institute Hospital, Japanese Foundation for Cancer Research |
| Gedeborg, 2021[39] | Mar to Dec, 2020 | Case-control | ADT | COVID-19 mortality | Prostate Cancer data Base Sweden (PCBaSe) RAPID 2019 |
| Gedeborg, 2021[7] | 2015 to 2020 | Retrospective cohort | ADT | COVID-19 mortality | Prostate Cancer data Base Sweden |
| Klein, 2021[8] | Mar to Jun, 2020 | Prospective cohort | ADT | COVID-19 positivity and disease severity | Cleveland, Ohio |
| Jiménez-Alcaide, 2021[9] | Mar to May, 2020 | Retrospective cohort | ADT | COVID-19 severity | Hospital Universitario Fundación Alcorcón |
| Koskinen, 2020[10] | Mar to May, 2020 | Retrospective cohort | ADT | COVID-19 positivity | Hospital District of Helsinki and Uusimaa, Finland |
| Schmidt, 2021[11] | Mar, 2020 to Feb, 2021 | Retrospective cohort | ADT | COVID-19 mortality | COVID-19 and Cancer Consortium registry |
| Kwon, 2021[12] | Feb to Dec, 2020 | Retrospective cohort | ADT | COVID-19 incidence | University of California Health System registry |
| Montopoli, 2020[5] | Start of COVID-19 to Apr, 2020 | Retrospective cohort | ADT | COVID-19 incidence | 68 hospitals in Veneto, Italy |
| Karimi, 2021[40] | Search: Dec, 2020 | Meta-analysis | ADT | COVID-19 infection risk, hospitalization rate, ICU admission, and mortality risk | Four eligible studies |
| Motlagh, 2022[15] | Search: July, 2021 | Meta-analysis | ADT | COVID-19 infection risk, severity | 6 Retrospective studies |
| Stroman, 2021[16] | Apr to May, 2020 | Cross-sectional | | Prostate biopsy method | Centres in United Kingdom |
| Caffo, 2020[41] | Feb to Jun, 2020 | Retrospective cohort | Metastatic castrate-resistant prostate cancer | COVID-19 incidence | 20 Italian oncological centres |
| Chakravarty, 2021[28] | Mar to Dec, 2020 | Retrospective cohort | Prostate cancer | COVID-19 hospitalization and mortality | Mount Sinai Hospital system |
| Deukeren, 2022[22] | Mar to May, 2020 | Cross-sectional | | Prostate cancer diagnosis | Netherlands Cancer Registry (NCR) |
| Fallara, 2021[23] | Mar to Jun, 2020 | Cross-sectional | | Prostate cancer diagnosis and staging, treatment | National Prostate Cancer Register (NPCR) of Sweden |
| Ferrari, 2021[19] | 2016 to 2020 | Cross-sectional | | Prostate cancer routine screening | University Hospitals of Verona |
| Klaassen, 2022[29] | Jan, 2018 to Mar, 2021 | Retrospective cohort | Race | Prostate biopsies and diagnoses | Veterans Affairs Health Care System |
| Bernstein, 2021[30] | Mar to May, 2020 | Retrospective Cohort | Race | Prostatectomy rate | Pennsylvania Urologic Regional Collaborative (PURC) |
| Nossiter, 2022[21] | Mar to Dec, 2020 | Cross-sectional | | Prostate cancer diagnosis and treatment | English National Health Service |
| Pepe, 2021[27] | 2020 to 2021 | Cross-sectional | | Prostate cancer diagnosis and treatment | Catania, Italy |
| Sciarra, 2020[20] | Mar 2020 | Descriptive study | | Diagnostic, therapeutic elective procedures requested and performed for cancer management | Rome, Italy |
| Surasi, 2021[18] | 2021 | Descriptive study | | Prostate MRI studies, biopsies | Radiologists from five continents |
| Ip, 2021[25] | Jun 2018 to Jun 2021 | Temporal trend analysis | | Cancer diagnostics, treatments, and physician attendances | Services Australia Medicare Benefits Schedule Item Reports |
| Kaufman, 2021[24] | Jan 2018 to Dec 2020 | Temporal trend analysis | | PSA, prostate biopsy, and diagnoses | Quest Diagnostics database |
| Barrett, 2021[42] | Jan 2019 - Oct 2020 | Analysis of descriptive statistics and interrupted time series | | Prescription of gonadorelins | English Prescribing Dataset |
| Ginsburg, 2020[32] | 2010 to 2016 | Retrospective cohort | Delayed radical prostatectomy | Oncological outcome | National Cancer Database |
| Lee, 2022[43] | 1988 to 2018 | Retrospective cohort | Delayed radical prostatectomy | Time of castration-resistant prostate cancer, metastasis, and all-cause mortality | SEARCH cohort, U.S. |
| Diamand, 2021[44] | Mar 2012 to Sep 2019 | Retrospective cohort | Delayed radical prostatectomy | Oncological outcome | European centers (Belgium, France, Switzerland, and Italy) |
| Zattoni, 2021[31] | Mar to Dec, 2020 | Retrospective Cohort | Delay in radical Prostatectomy | Risk of adverse pathologic findings at RP | 8 European tertiary referral centers |
| Chan, 2021[33] | Search: May, 2020 | Meta-analysis | Delayed treatment | Disease prognosis | 4 randomized trials and 33 observational studies |
| Loeb, et al. 2021[45] | Dec 2019 to April 2020 | Computational linguistic ethnography analysis | Prostate cancer | Linguistic tone and topic of discussion online | Inspire Us TOO Prostate Cancer online support and discussion, Reddit |
| Irusen, 2021[46] | Jul to Sep, 2020 | Prospective longitudinal study | COVID-19 | Corona virus anxiety scale, state-trait anxiety inventory, the connor-davidson resilience scale, and multidimensional scale of perceived social support | Cape Town, South Africa |
| Araújo, 2022[35] | Before vs after COVID-19 pandemic | Prospective Cohort | ADT | Montreal cognitive assessment | NEON-PC, Portuguese Institute of Oncology of Porto |
| Kizilkan, 2021[34] | Mar to Jun, 2020 | | | State-trait anxiety inventory I and II and beck depression inventory | Ankara City Hospital, Turkey |
| Lopez, 2020[47] | Search: Nov, 2019 | Meta-analysis | | Fatigue, quality of life, lean body mass, and fat mass | 3 randomized trials |
| Liontos, 2021[37] | 2021 | Prospective cohort | Prostate cancer under treatment with ARTA who were vaccinated for COVID-19 | Neutralizing antibody against COVID-19 | Athens, Greece |
| Notohamiprodjo, 2022[48] | Jun to July, 2021 | Retrospective cohort | COVID-19 vaccination | Prevalence, temporal response, and characteristics of vaccine-associated lymphadenopathy | Munich, Germany |